Bristol-Myers Squibb (BMY) FDA Approves Breyanzi for Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Visit StreetInsider.com at http://www.streetinsider.com/Hot+FDA+News/Bristol-Myers+Squibb+%28BMY%29+FDA+Approves+Breyanzi+for+Relapsed+or+Refractory+Chronic+Lymphocytic+Leukemia+or+Small+Lymphocytic+Lymphoma+/22934718.html for the full story.

Leave a Reply

Your email address will not be published. Required fields are marked *